How intestinal cancer stem cells evade anti-angiogenic therapy

How intestinal cancer stem cells evade anti-angiogenic therapybyLudwig Cancer ResearchCredit: CC0 Public DomainA team led by Ludwig Lausanne's Tatiana Petrova, Jeremiah Bernier-Latmani and a

Updated on: October 30,2023

How intestinal cancer stem cells evade anti-angiogenic therapy

How intestinal cancer stem cells evade anti-angiogenic therapybyLudwig Cancer ResearchCredit: CC0 Public DomainA team led by Ludwig Lausanne's Tatiana Petrova, Jeremiah Bernier-Latmani and a

Updated on:October 30,2023

First-in-human trial for new lung cancer immunotherapy

byCancer Research UKCancer Research UK and Vaccitech Oncology Limited (VOLT), today (Wednesday) announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lu

Updated on: December 22,2023

First-in-human trial for new lung cancer immunotherapy

byCancer Research UKCancer Research UK and Vaccitech Oncology Limited (VOLT), today (Wednesday) announce a new partnership to bring a novel immunotherapeutic vaccine strategy to patients with lu

Updated on:December 22,2023

Basic research opens up new therapeutic opportunities for fighting leukemia

byUniversity of Veterinary Medicine—ViennaGenome-wide CRISPR/Cas9-based loss-of-function screen identifies genetic dependencies of STAT3Y640F-driven cells a) Schematic illustration of a competit

Updated on: December 25,2023

Basic research opens up new therapeutic opportunities for fighting leukemia

byUniversity of Veterinary Medicine—ViennaGenome-wide CRISPR/Cas9-based loss-of-function screen identifies genetic dependencies of STAT3Y640F-driven cells a) Schematic illustration of a competit

Updated on:December 25,2023

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29, 2023Kyle DohertyThe addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma w

Updated on: October 12,2023

Pembrolizumab With COPDAC-28 Consolidation Increases PET Negativity in Classical Hodgkin Lymphoma

August 29, 2023Kyle DohertyThe addition of pembrolizumab to COPDAC-28 consolidation may augment responses to treatment in pediatric and young adult patients with high-risk classical Hodgkin lymphoma w

Updated on:October 12,2023

BRAF Mutation: Cancer Types, Testing, Treatment

BRAF Mutation: Cancer Types, Testing, TreatmentRole of BRAF mutations in melanoma, lung cancer, and moreByLynne Eldridge, MDUpdated on October 14, 2022Medically reviewed byOliv

Updated on: January 28,2024

BRAF Mutation: Cancer Types, Testing, Treatment

BRAF Mutation: Cancer Types, Testing, TreatmentRole of BRAF mutations in melanoma, lung cancer, and moreByLynne Eldridge, MDUpdated on October 14, 2022Medically reviewed byOliv

Updated on:January 28,2024

New blood test revolutionizes early cancer detection in Li-Fraumeni Syndrome patients

In a study published inCancer Discovery, researchers from Canada tested the use of a multimodal liquid biopsy assay based on cell-free DNA (cfDNA) for early cancer detection in patients with Li-

Updated on: October 30,2023

New blood test revolutionizes early cancer detection in Li-Fraumeni Syndrome patients

In a study published inCancer Discovery, researchers from Canada tested the use of a multimodal liquid biopsy assay based on cell-free DNA (cfDNA) for early cancer detection in patients with Li-

Updated on:October 30,2023

Improving treatment for hairy cell leukemia

by Melissa Rohman,Northwestern UniversityCredit: Unsplash/CC0 Public DomainPatients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent respon

Updated on: December 22,2023

Improving treatment for hairy cell leukemia

by Melissa Rohman,Northwestern UniversityCredit: Unsplash/CC0 Public DomainPatients with relapsed or refractory hairy cell leukemia who were treated with vemurafenib experienced excellent respon

Updated on:December 22,2023

Novel drug shows promising efficacy for patients with multiple myeloma

by Jenny Owen,Emory UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDResults of an international clin

Updated on: December 18,2023

Novel drug shows promising efficacy for patients with multiple myeloma

by Jenny Owen,Emory UniversityScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDResults of an international clin

Updated on:December 18,2023

Technology that determines success of CAR T-cell immunotherapy could advance treatment of lymphoma

by Laurie Fickman,University of HoustonNavin Varadarajan, M.D. Anderson Professor of chemical and biomolecular engineering, studied the dynamic interactions between T cells and tumor cells to de

Updated on: December 26,2023

Technology that determines success of CAR T-cell immunotherapy could advance treatment of lymphoma

by Laurie Fickman,University of HoustonNavin Varadarajan, M.D. Anderson Professor of chemical and biomolecular engineering, studied the dynamic interactions between T cells and tumor cells to de

Updated on:December 26,2023

What you need to know after a breast cancer diagnosis

by Robin FosterBreast cancer strikes 1 in 8 women in the United States, but being diagnosed with the disease can still make you feel alone.To cope with such devastating news, breast cancer surgeons fr

Updated on: October 24,2024

What you need to know after a breast cancer diagnosis

by Robin FosterBreast cancer strikes 1 in 8 women in the United States, but being diagnosed with the disease can still make you feel alone.To cope with such devastating news, breast cancer surgeons fr

Updated on:October 24,2024

Analyzing a Study on the Therapeutic Potential of Targeting IL-20RB in Lung Cancer Bone Metastasis

Updated on: September 15,2024

Analyzing a Study on the Therapeutic Potential of Targeting IL-20RB in Lung Cancer Bone Metastasis

Updated on:September 15,2024

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on: December 21,2023

Significant treatment attrition rate seen in multiple myeloma

by Elana GotkineThere is a significant treatment attrition rate in newly diagnosed multiple myeloma (NDMM), according to a study published in the November issue ofLeukemia & Lymphoma.Victor

Updated on:December 21,2023